In silico study of potential antiviral activity of copper(II) complexes with non-steroidal anti-inflammatory drugs on various SARS-CoV-2 target proteins다양한 SARS-CoV-2 표적 단백질에 대한 비스테로이드성 항염증제와 구리(II) 복합체의 잠재적 항바이러스 활성에 대한 실리코 연구Article Published on 2022-06-012022-09-11 Journal: Journal of inorganic biochemistry [Category] COVID19(2023년), SARS, 치료제, [키워드] 3C–like cysteine main protease antiviral activity Antiviral agents biological activity Cancer cell line clonixin complex complexes copper coronavirus 2 Coronavirus 2019 COVID-19 cysteine cytotoxic cytotoxic activity distribution drug-likeness evaluated fenoprofen FIVE ibuprofen in silico in silico predictive tools. in vitro ligands loxoprofen M pro metabolism molecular docking studies non-steroidal anti-inflammatory drug Non-steroidal anti-inflammatory drugs non-structural protein non-structural proteins nsp10 Nsp16–Nsp10 2′–O–methyltransferase complex Nsps pandemic Papain-like protease Papain–like protease performed pharmacokinetic pharmacokinetic data physicochemical PLPro Predictive protease Protein RdRP respiratory RNA RNA-dependent RNA polymerase RNA–dependent RNA polymerase SARS-CoV-2 SARS–CoV–2 target proteins Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus silico predictions target protein target proteins therapeutic target Toxicity [DOI] 10.1016/j.jinorgbio.2022.111805 PMC 바로가기 [Article Type] Article
Australian consensus recommendations for the management of hepatitis BArticle Published on 2022-05-162023-06-11 Journal: The Medical journal of Australia [Category] B형 간염, [키워드] Antiviral agents hepatitis B Hepatitis, viral [DOI] 10.5694/mja2.51430
Indole alkaloids as potential candidates against COVID-19: an in silico studyCOVID-19에 대한 잠재적 후보로서의 인돌 알칼로이드: 실리코 연구Article Published on 2022-05-112022-09-11 Journal: Journal of molecular modeling [Category] COVID19(2023년), SARS, 치료제, [키워드] active site analyses antiviral agent Antiviral agents applied binding energy binding free energy calculation candidate classical Compound COVID-19 docking docking process effective drug effective drugs effort enzyme free energy Human identify IMPROVE in silico in viral indole Indole alkaloids inhibitor Interaction ligands M pro MM-PBSA molecular molecular dynamic simulations pandemic plant protease Replication SARS-CoV-2 SARS-CoV-2 main protease SARS-CoV-2 main protease inhibitor selected Side effects survival the SARS-CoV-2 therapeutic option therapeutic options therapeutic target Transcription treat Treatment treatment of COVID-19 viral replication Virtual screening was performed [DOI] 10.1007/s00894-022-05137-4 PMC 바로가기 [Article Type] Article
Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study한국에서 중등도 SARs-CoV-2 환자에 대한 3세대 세팔로스포린, 아지트로마이신 및 항바이러스제 병용 치료: 후향적 코호트 연구Article Published on 2022-05-042022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 치료제, [키워드] adjust administration adverse event Analysis analyzed Antibiotics antiviral agent Antiviral agents association Azithromycin baseline characteristics cephalosporin Clinical outcome Cohort cohorts Combined combined treatment conducted confounding factors COVID-19 COVID-19 patient Cox regression analysis Cox regression method death Efficacy and safety Endpoint endpoints Evidence groups hazard ratio hazard ratios Hospital stay Hydroxychloroquine inclusion criteria Kaplan-Meier Kaplan-Meier curve Kaplan-Meier curves laboratory-confirmed Lopinavir Lopinavir/ritonavir low-dose mild to moderate Mild to moderate COVID-19 moderate Moderate COVID-19 moderate COVID-19 patients no significant difference no significant differences not significant Patient performed Prevent Propensity score propensity score matching PSM retrospective cohort study Ritonavir SARS-CoV-2 SARS-CoV-2 patient SARS-CoV-2 patients significant differences South South Korea Standard standard supportive care statistical significance Supportive treatment symptom resolution Time to symptom resolution Treatment treatment arm treatment group viral clearance were used [DOI] 10.1371/journal.pone.0267645 PMC 바로가기 [Article Type] Article
Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors조합 AAV/RNAi 발현 벡터를 사용한 SARS-CoV-2의 생체외 및 생체내 억제Article Published on 2022-05-042022-09-11 Journal: Molecular therapy : the journal of the American So [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] AAV acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition adeno-associated virus Antiviral Antiviral agents antiviral RNAi Cell clinically cocktail complement coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 disease symptom effective escape mutant escape mutants experiment expression vector flexible Genetic global effort Gut hACE2 in vivo infected cell infected cells intestinal cells intranasal mice mutational escape. N gene N genes organoids pandemic prevented RdRP RNA RNAi SARS virus SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RdRp SARS-CoV-2 strains severe acute respiratory syndrome Coronavirus suppressed the SARS-CoV-2 therapeutic translation triggers Vaccine vector vectors viral adaptation Viral load viral loads virus wild-type [DOI] 10.1016/j.ymthe.2022.01.024 PMC 바로가기 [Article Type] Article
Synthesis and in vitro Study of Artemisinin/Synthetic Peroxide-Based Hybrid Compounds against SARS-CoV-2 and CancerSARS-CoV-2 및 암에 대한 아르테미시닌/합성 과산화물 기반 하이브리드 화합물의 합성 및 시험관 내 연구Article Published on 2022-05-042022-09-11 Journal: ChemMedChem [Category] COVID19(2023년), SARS, 치료제, [키워드] active against acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 analyzed anti-cancer compounds anti-leukemia agents anti-SARS-CoV-2 anti-SARS-CoV-2 compounds antiviral agent Antiviral agents Artemisinin artemisinin based hybrids. artesunic acid Cancer Cell cell lines Compound coronavirus cytotoxic effect cytotoxic effects demonstrated disease Doxorubicin drug effective hybrid hybrid drug in vitro in vitro activity Infection inhibitory activity leukemia life-threatening Patients with cancer peroxide quinoline reported SARS-CoV-2 SARS-CoV-2 infections selectivity severe acute respiratory syndrome Coronavirus synthesis treat Vero E6 Vero E6 cell VERO E6 cells while [DOI] 10.1002/cmdc.202200005 PMC 바로가기 [Article Type] Article
Peptides-based therapeutics: Emerging potential therapeutic agents for COVID-19펩티드 기반 치료제: COVID-19에 대한 새로운 잠재적 치료제Review Published on 2022-05-012022-09-11 Journal: Thérapie [Category] Coronavirus, COVID19(2023년), SARS, 신약개발, 임상, 치료제, [키워드] antimicrobial peptide antiviral activity Antiviral agents blocked causative agent cell membrane cleave clinical trials COVID-19 COVID-19 outbreak drug drugs feasibility form fusion hACE2 host cell host cell membrane Human humans In silico method inhibitor Interaction intestine intestines lactoferrin lung Lungs mechanism MERS outbreak pandemic peptide peptide-based peptides Peptides-based therapeutics positive-sense RNA virus potential therapeutic agent RNA virus S protein S protein-hACE2 interaction S1 subunit S2 subunit SARS-CoV-2 shown the S1 subunit the SARS-CoV-2 therapeutic viral envelope viral infection [DOI] 10.1016/j.therap.2021.09.007 PMC 바로가기 [Article Type] Review
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?COVID-19와 소분자 치료제의 약속: 배워야 할 교훈이 있습니까?Review Published on 2022-05-012022-09-11 Journal: Pharmacological research [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjuvant therapy Antiviral antiviral agent Antiviral agents antivirals Baricitinib Baricitinib (PubChem CID: 44205240) Chloroquine Chloroquine (PubChem CID: 2719) coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Critical developmental Dexamethasone Dexamethasone (PubChem CID: 5743) drug Drug discovery effective Endemic Healthcare professional healthcare professionals Hydroxychloroquine Hydroxychloroquine (PubChem CID: 3652) Inclusion Ivermectin Ivermectin (PubChem CID: 6321424) limitation Lopinavir Lopinavir (PubChem CID: 92727) molnupiravir Molnupiravir (Pubchem CID: 145996610) Nirmatrelvir Nirmatrelvir (PubChem CID: 155903259) pandemic provided PubChem Remdesivir Remdesivir (PubChem CID: 121304016) researcher Retrospective analysis Ritonavir Ritonavir (PubChem CID: 392622) SARS-CoV-2 severe acute respiratory syndrome Coronavirus small molecule Small molecule therapeutics. standstill tested the disease therapy Treatment treatment of COVID-19 while with COVID-19 [DOI] 10.1016/j.phrs.2022.106201 PMC 바로가기 [Article Type] Review
Nonsignificant trends in COVID-19 trials: Is there a significance?COVID-19 임상시험의 중요하지 않은 경향: 의미가 있습니까?Article Published on 2022-05-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료제, [키워드] Affect Antiviral Antiviral agents antiviral drug antiviral drugs baseline claimed clinical trial clinical trials conducted coronavirus Course COVID-19 COVID‐19 example explained groups mechanical ventilation on mechanical ventilation Patient positive provided SARS Coronavirus severity solidarity statistical analysis statistical significance statistically significant survival Treatment virus virus classification [DOI] 10.1002/jmv.27565 PMC 바로가기 [Article Type] Article
Therapeutic strategies to fight COVID-19: Which is the status artis?COVID-19와 싸우기 위한 치료 전략: 어떤 상태가 예술입니까?Review Published on 2022-05-012022-09-11 Journal: British Journal of Pharmacology [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] Analysis anniversary anti-inflammatory drug Anticoagulants antiviral agent Antiviral agents approach approval article Clinical research clinical trials complex convalescent plasma Corticosteroids COVID COVID-19 Critically ill Critically ill patient disease drug Efficacy and safety European country Evidence Health Organization heparin heparins Hospitalized immunomodulatory investigated patients with COVID-19 pharmacological treatments phase Phase III clinical trials repurposing drugs review robust second wave supported The United States Treatment United States use of corticosteroid Vaccine Vaccines Vitamin D WHO World Health Organization [DOI] 10.1111/bph.15452 PMC 바로가기 [Article Type] Review